ArriVent BioPharma, Inc. financial data

Symbol
AVBP on Nasdaq
Location
18 Campus Blvd., Suite 100, Newtown Square, PA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.38K % -38.1%
Debt-to-equity 7.04 % +5.39%
Return On Equity -59.7 % -35.9%
Return On Assets -55.7 % -87.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41.3M shares +22.5%
Common Stock, Shares, Outstanding 40.9M shares +21.2%
Entity Public Float 384M USD
Common Stock, Value, Issued 4K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 41.9M shares +24.8%
Weighted Average Number of Shares Outstanding, Diluted 41.9M shares +24.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 141M USD +79.2%
General and Administrative Expense 21.1M USD +41.7%
Operating Income (Loss) -162M USD -73.3%
Net Income (Loss) Attributable to Parent -151M USD -86.8%
Earnings Per Share, Basic -4 USD/shares +50.7%
Earnings Per Share, Diluted -4 USD/shares +50.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 113M USD -60.2%
Assets, Current 321M USD +9.86%
Operating Lease, Right-of-Use Asset 49K USD -73.8%
Other Assets, Noncurrent 180K USD +42.9%
Assets 327M USD +11.6%
Accounts Payable, Current 5.93M USD +27.7%
Employee-related Liabilities, Current 4.39M USD +39%
Accrued Liabilities, Current 15.6M USD +50.3%
Liabilities, Current 21.6M USD +42.2%
Operating Lease, Liability, Noncurrent 14K USD -92.1%
Liabilities 21.6M USD +41.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 206K USD
Retained Earnings (Accumulated Deficit) -369M USD -69.5%
Stockholders' Equity Attributable to Parent 305M USD +9.91%
Liabilities and Equity 327M USD +11.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -68M USD -265%
Net Cash Provided by (Used in) Financing Activities 6.76M USD -96.4%
Net Cash Provided by (Used in) Investing Activities 36.8M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 40.9M shares +21.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -24.4M USD -115%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 113M USD -60.2%
Deferred Tax Assets, Valuation Allowance 68.8M USD +55.9%
Deferred Tax Assets, Gross 68.8M USD +55.8%
Operating Lease, Liability 176K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -151M USD -69%
Lessee, Operating Lease, Liability, to be Paid 187K USD
Operating Lease, Liability, Current 56K USD -64.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 14K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 173K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11K USD
Deferred Tax Assets, Operating Loss Carryforwards 16.7M USD +78.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 674M USD +36.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 39K USD -44.3%
Share-based Payment Arrangement, Expense 10.3M USD +330%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%